Thank you, and welcome everybody to the presentation of Nolato's first quarter 2021. This is Christer Wahlquist speaking. I think that you all have our presentation in front of you. If we start on page two, the first quarter of 2021 was a record quarter for Nolato Group. We did reach the strongest sales and profit in our history so far. Sales amounted to more than SEK 2.6 billion, corresponding to a 22% increase in sales if we adjust for currency and acquisitions. We have, of course, GW Plastics has been consolidated since September 1st. The integration is going according to plan. During the quarter, we had a negative currency effect, mostly affecting the conversions. The EBITA profit increased to SEK 308 million in the first quarter in comparison to the first quarter 2020, that was SEK 227 million. This is creating a margin of 11.6% for the group, so we consider that a strong margin. Cash flow during the first quarter after investments are increased and improved in correspondence to last year and amounted to SEK 71 million. Turning to page three. We have created a balanced group with three strong business areas. All of the three business areas are now present on three, for us, most important continents, that is Asia, Europe, and Americas. If we jump into Medical Solutions business area on page four, you will see a graph of our sales over 20 years, and we can consider this 20 years of strong growth. We have had organic growth every year, and we are now in a geographical expansion combined with the technology journey with the business area Medical Solutions. If we look into the different segments of the Medical Solutions business area on page five, you will see the six most important areas that we are operating in. To mention a few, we have the in vitro diagnostics, which of course is positively impacted by the COVID-19 situation. We have continence care being a large portion of our group. We have endoscopy and general surgery that is negatively impacted by the COVID-19 situation. Drug delivery systems, which, of course, are different delivery systems for bio drugs and other drugs that need to be injected into the body. We consider it being a good split of sales between different interesting therapeutical areas that all have good possibilities for future growth. If we turn to page six, focusing a little bit more deeper on the numbers for Medical Solutions. During the first quarter, we had a 57% increase in sales. If we adjust for the GW Plastics acquisition and currency effect, it was still a very strong 17% increase in sales. We saw a high demand in diagnostics, which is growing partly because of the pandemic. During the quarter, we had a high level of billing for development work and production equipment, and I would say that approximately boosted for sort of extraordinary sales, SEK 70 million. We saw during the quarter weak demand in surgical segment, specifically in the U.S. business, due to postponed operations due to the pandemic, but we saw a slightly better end to the quarter in this area. The margin ended up at 12%, and of course, this is a strong margin if we put into this lower margin that we have from the latest acquisitions of GW Plastics. The sales in the quarter exceeded SEK 1 billion and a profit of SEK 121 million. We are expanding our production capacity, and previously we had decided to expand in Switzerland, Hungary, Sweden, and this is according to plan, proceeding good. We have made new decisions on capacity expansions in Poland and in the U.S. If we then turn to page seven, to focus a little bit on the Integrated Solutions business area. If we look on the 20-year graph of this business area, I would say up till 2016, this was a telecom business area, and since then, we have successfully expanded our operations into new market segments with similar needs as the telecom market. We are now in that mode of expanding our business. If you turn to page eight, describing a little bit about the two parts to this business area. We have the largest portion, which is consumer electronics, consisting of VHP, different connected Wi-Fi systems, wearables, and mobile phones. We have the EMC thermal part of the business. It's a lot about material science and the solutions for thermal management and electromagnetic shielding. This business was built within the telecom and now expanding to new market areas. If you turn to page nine, focusing on the details of Integrated Solutions. We had a very good quarter with a 40% increase in sales during the quarter. We had strong sales both in the consumer electronic and the EMC thermal segments. The growth was, of course, based on the good volumes within the VHP area, but also strong growth within EMC and dependent on the rollout of the 5G and good initiatives within the automotive sector that are performing very well. We also expect the second quarter to increase sales by around 15% compared to the first quarter this year. During the quarter, we had sales of a little bit more than 1 billion SEK, with an operating profit, EBITDA, of 125 million SEK, giving an EBITDA margin of 12%. If we turn to page 10, and focusing a little bit on the Industrial Solutions business area. Here's also a 20-year graph of our sales, and we have, during the last period of time, established industrial on the three important continents. If you look into the business area on page 11, we have two parts to the business area, the largest portion being the general industry that are working with large global customers within the industrial sector, and the smaller and other part of the business area is automotive, where we are mostly focusing on the Scandinavian automotive industry. If we turn to page 12 and focus on the numbers for the first quarter. During the first quarter, our sales amounted to SEK 595 million, with an operating profit of SEK 66 million, creating a strong margin of 11.1%. That is corresponding to 4% increase in sale. If we adjust for currency and acquisition, it was an increase of 1%. It was slightly affected by the shortage of components within this area. We turn to page 13. Good afternoon. This is Per-Ola Holmström, and I will comment on group financial highlights on page 13. In the left columns, you can see numbers for Q1 2021 compared to last year, the same quarter. The consolidated numbers have a combination of increased sales and improved margin compared with Q1 last year. The sales ended up just above SEK 2.6 billion, with an operating EBITA result of SEK 308 million. That is resulting in an EBITA margin of 11.6%. A few lines below, you can see the tax rate for the group. It has increased compared to the same period last year, 21.0%. The increased effect came from the bigger operation we have in U.S. since the U.S. acquisition last year. Cash flow after investments, that was SEK 71 million compared to minus SEK 73 last year. The improvement in cash flow was due to increased profit and a smaller rise in working capital requirements compared with the same period last year. It was also partly offset by increased investments. As you can see on the next line, the investments in this quarter was SEK 178 million, compared to only SEK 70 million last year. Of course, there is an effect of a bigger operation, including GW Plastics. We expect the full year investments to be around SEK 650 million. Earnings per share were SEK 8.43. If we exclude amortization of intangible assets from acquisitions, that number is SEK 8.69. Balance sheet net financial liabilities, if we exclude pension and lease liabilities, ended up with minus SEK 258 million. A year ago, we hadn't done the acquisition. Then we had a net cash position at SEK 601 million. The cash conversion increased further during the last 12 months to 95%. At last year, 2020, the same number was 87%. Turning to page 14, some comments on our current situation per business area. If we start with Medical Solutions, we have maintained growth strategy for this business. A lot of focus on innovation, of course, based on very strong customer relationships. We see achievement of synergies across markets. This business area, of course, have been some impact of the pandemic, with the situation that a lot of surgeries are put on hold, but on the other hand, we see an increase in the diagnostics side. If we look on Integrated Solutions, we have strongly established position in new product areas. We are continued very strong position within EMC and Thermal. We see the 5G rollout and new automotive initiatives that is positive for EMC. Of course, all based on our flexible production structure. If we look into Industrial Solutions, we have advanced our market positions. We are very successful in our efficiency improvements. Of course, this business area has been impacted by the pandemic and a lot of emphasis on sustainable solutions. Thank you. We now open up for questions. Thank you. Ladies and gentlemen, if you do wish to ask a question, please press 01 on your telephone keypad now. That is zero one to register for a question. We have a question from the line of Carl Ragnerstam from Nordea. Please go ahead. Hi, it's Carl Ragnerstam here from Nordea. A few questions from my side. Firstly, on the Medical Solutions side, you guided that you see a slight uptick in the surgical segment. Could you firstly comment if it's purely in the U.S. or Europe as well? Secondly, could you also try to quantify the uptick that you see? I think the uptick in surgical is mostly, or most seen in the U.S., so that is what it's relating to. Okay. Of course, the uptick in itself is not dramatic. We saw an increase during the last part of the quarter. Okay, perfect. On the IVD sub-segment, you also said that you saw quite strong performance there in the quarter as well. Is it fair to assume still or continued higher levels in Q2 or maybe going into Q3 as well? Is it maybe difficult to say given quite poor visibility? I would anticipate the strong performance to continue in IVD. Perfect. On the equipment side, you have previously said that, or I guess that equipment volumes are a bit hampered because of low traveling or traveling restrictions. Now we obviously saw quite the massive impact here in Q1. Is that a one-time effect, or is it the pent-up demands sort of there, or how should we look at that? I think we commented previously that we saw some, how should I say, some difficulties in performing development work for customers. In this quarter, it was a specific uptick during this quarter with some extraordinary sales. Okay, perfect. The final one from my side is that you're guiding that you're taking the decision to expand Poland and the U.S. operations. How much capacity are you adding, and are you also willing to give some guidance on CapEx there? You obviously gave full-year guidance, but specifically these projects. The numbers for these investments in new CapEx and expansion, it is included in the SEK 650 million, which I referred to earlier. It's part of that, we do have a major part of the investments or CapEx within medical. Of course, these expansions are a very large part of that going forward. Of course, including buildings in some cases, clean rooms, infrastructure around that, and the first steps of machinery in those areas. It is very much around those expansions. As we list most of the countries we do have, it is, of course, a major part of the CapEx as well. Is it related to any sub-segment? Is it the surgical side, or could you specify that? I would not specifically put it into a sub-segment, more general expansion of capacity. Okay, perfect. All from my side. Thank you. Thank you. Our next question comes from the line of Erik Cassel from ABG Sundal Collier. Please go ahead. Hi, [Christian Frolov]. My first question is on the margin and contract for VHP in Integrated Solutions. If I understood it correctly, that is sort of a fixed margin contract. Now with plastic costs increasing, is it fair to assume that it also applies when you see increasing costs, so that we should sort of see impact margins and increased sales into H2 for that? Yes, there is a mathematical effect, as you say. We do see that in many areas today, and you can read about it in the press every day. It's not only the plastic, it's different kind of raw materials increasing. We have technical plastics, and the increases are not that dramatic that you could see in some of the more basic plastics. Still, it's high increases, and of course, you get those effects when we add that to the pricing we did have before. That is the way we handle it, and that's according to contracts that we have with most of our customers. Okay, it's fair to assume that the margin impact would be limited in any case? Yeah. No major effects because of that. We do see some time lags, but it's nothing big that affects very much. Okay, perfect. Thank you. Also for Integrated Solutions. The margin has been close to 12% now for two quarters in a row, which is a bit lower than the 13%-14% we have seen over the past two years. Is this related to the sort of cost and price changes you implemented in Q3 and Q4, mean that this should sort of be considered as a normal margin from now on? Yes, I think as you did see, and as you comment, we have had those kind of margins the last two quarters. These two quarters do have the latest product variants within them, and that is the situation we are in right now with currency effects and everything in it. If you do recall, if we go back to some of the quarters where we did have 13%+ margins, some of those also had a positive effect from Chinese subsidies that we did get in some of these quarters. That is what we have seen the last two quarters. That's correct, yes. Okay, perfect. That was all from me, so thank you very much. Thank you. I'll remind you that if you want to ask a question, please press zero one on your telephone keypad now. We have a question from the line of Mikael Laséen from Carnegie. Please go ahead. Hi, a few questions from me. Can you elaborate a bit more on the GW Plastics side, how that company is developing organic growth in the quarter and the margin situation for them? Yes. The integration of GW Plastics is going very good. Of course, we see some effects of the pandemic with the slowdown in the surgical, but we are very pleased with the acquisition and going in a good way. Okay. Excluding the surgical side, are the other product areas growing by 5%, 10%, or are they also affected? The effect from the pandemic, that is affecting, of course, the surgical, and to some extent, part of the automotive. Okay. I can also add to that you did see the comment we have that we have seen a slightly improved margin in this quarter compared to the fourth quarter last year. Okay. In local currencies, sales were roughly similar to the fourth quarter. We are in a similar situation, and as Christer Wahlquist commented on the surgical side, a similar situation as well. Okay. Can you give us the FX effects on revenue for the group and for each segment, please? Yes, I can. We did have the largest ones in Integrated Solutions, as we usually have. Those were SEK 150 million, if we convert all of them. We lost SEK 150 million compared to the same quarter last year if we would have kept the same currency rates as Q1 last year. In medical, we lost SEK 40, and in Industrial Solutions, half of that, SEK 20. Okay, great. That's helpful. It's SEK 210 on group level. Okay, got it. When it comes to Integrated Solutions, the guidance for 15% quarter-on-quarter growth in Q2, would be interesting to hear input on the inventory situation, or if this is driven by underlying end consumer demand. Of course, there are constantly some movements on the inventory, but we anticipate the market is growing. Okay. There is not an unusual inventory situation than in Q2, I guess. We are not anticipating that, no. Okay, good. When it comes to plastic input cost, you already talked a bit about that, but what type of cost price increases are we talking about here on the more technical side for advanced materials? I think to start with, we have to be aware that only part or a smaller part of our purchasing is coming from pure plastics. We try to explain that within Industrial, we have the highest level of plastic content. The medical is lower and also Integrated. It's only part of it which is really hit by this. Of course, we do see a number of different changes all over the large palette of different plastics that we buy. Of course, some extremes, but some areas which haven't moved much at all. It's a different mix to smaller parts of our purchasing. That is where this is seen. It also, of course, happens over time, so it's not everything in one month. We have, of course, inventory as well, which we have been buying to lower prices. It's a mixing situation where this adds on during different time periods. It's also reflected by inventory situations and different things going the other direction also. What we see is the net of all those things going on combined with how we take out this on our customers. It's a mix of different things, a complex situation, and of course, we work a lot with it. Yeah, interesting. Thanks. One final maybe. The component shortage situation now has been discussed a lot, of course, in the reporting season and before that. How are you affected by it? What do you see ahead, especially for the industrial segment? I think we have had limited effects from this and been in a fortunate situation where our products have been prioritized by customers and so on. We are, of course, following this very closely, and it could affect us, but so far, very limited. Okay, thanks. That's it from me. Thank you. There are no further questions registered. I am back to the speakers for any closing remarks. Thank you very much for listening to the presentation of the latest first quarter, and I wish you all a great end of the day. Thank you.